

Public Posting FDA-RFQ-133298

06/25/2026

The Center for Drug Evaluation and Research (CDER), Office of Testing and Research requires the purchase of an Alberta Idealized Nasal Inlet (AINI), or equivalent instrument, with an Alberta Nasal Leak (or equivalent) test kit. The AINI will be installed on Copley Scientific Next Generation Impactor (NGI) and Fast Screening Impactor (FSI) testing devices to be used for nasal deposition testing of spray dried powders for intranasal drug delivery.

Delivery, installation, verification/qualification tests, and onsite training shall be completed within 90 days of contract award at the below address:

US Food and Drug Administration (FDA)
Center for Drug Evaluation and Research (CDER)
Office of Testing and Research
10903 New Hampshire Ave, Lab WO 64, Rm 1083
Silver Spring MD 20993

For more information regarding this requirement (FDA-RFQ-133298) please contact Suzanne Martella email at suzanne.martella@fda.hhs.gov or by phone at 301-796-2383.

All responsible sources may submit a response which, if timely received, must be considered by the agency. Responses are due by 3:00PM Central Time on 07/01/2026.